Pivotal readout

Kelun ADCs Gain Reimbursement

Two additional indications for sacituzumab tirumotecan and the first indication for botutumab vedotin were added to China's national reimbursement directory, effective January 1, 2027. The newly reimbursed sacituzumab tirumotecan indications cover eligible patients with EGFR-mutated non-small cell lung cancer and HR-positive, HER2-negative breast cancer. Kelun-Biotech says all its marketed products and approved indications are now covered; botutumab vedotin previously showed improved progression-free survival versus T-DM1 in a phase 3 trial.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call